Stockreport

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BIO-PATH HOLDINGS INC  (BPTH) 
Last bio-path holdings inc earnings: 11/14 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: biopathholdings.com
PDF HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and a [Read more]